MA2625
Anti-HPV18 Monoclonal Antibody, 人源化抗HPV18/HPV45抗体，人类乳头瘤病毒抗体，HPV中和抗体，HPV阻断抗体，HPV治疗性抗体，Anti-HPV18 L1 Monoclonal antibody, Anti-HPV18 neutralizing antibody, HPV18 recombinant antibody, Human papillomavirus type 18 antibody, Anti-HPV45 Monoclonal Antibody, An
| Catalog Number | MA2625 |
| Alias | Anti-HPV18 Monoclonal Antibody, 人源化抗HPV18/HPV45抗体，人类乳头瘤病毒抗体，HPV中和抗体，HPV阻断抗体，HPV治疗性抗体，Anti-HPV18 L1 Monoclonal antibody, Anti-HPV18 neutralizing antibody, HPV18 recombinant antibody, Human papillomavirus type 18 antibody, Anti-HPV45 Monoclonal Antibody, An |
| Size | 100ug, 500ug, 1mg |
| Product Description | The Human Anti-HPV18/HPV45 mAb (MA2625) can be used in ELISA and Neutralization test and is suitable for other immunoassay applications. |
| Host | Human |
| Clonity | Monoclonal |
| Purity | > 90% as determined by SEC-HPLC |
| Storage Condition | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Avoid repeated freeze-thaw cycles. |
| Formulation | PBS, pH7.4 |
| Shipping Condition | Shipped on ice packs. |
| Background | HPV is a double-stranded circular DNA virus. HPV infection is the most prevalent sexually transmitted disease, which results in over 14000000 individuals annually and 80% of sexually active individuals in their lifetime to be infected from HPV. As of September 2023, 231 HPV types have been identified. Different types of human neoplasia (HPV) cause different types of disease. The two HPV types, HPV16 and HPV18, have been identified as the most prevalent types associated with cervical cancer and are accountable for 70% of cervical cancers and precancerous cervical lesions. The human papillomavirus 9-valent recombinant vaccine has VLPs for two low-risk HPV6 and seven high-risk HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58. This vaccine can prevent 90% of cervical cancers and 90% of genital warts. |
| Application | ELISA, Neutralization |
| Biological Activity | The neutralization activity is measured by microneutralization assay in vitro. The infection was neutralized by increasing concentrations of Anti-HPV Neutralizing Antibody. IC50(HPV18) is 0.9 ng/mL. IC50(HPV45) is 1.1 ng/mL. |
| Product Declaration | 该产品仅供科研使用，不可直接用于人体或注射。 |
销售微信
官方公众号
0
